Grace Jinfeng Rilee

Ms. Grace Jinfeng Rilee


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2024 in Bioorganic Chemistry
Verified
Journal Article
Closed access
SZShadid U. Zaman
Shadid U. Zaman
PPPiyusha Pagare
Piyusha Pagare
BHBoshi Huang
Boshi Huang
GRGrace Jinfeng Rilee
Grace Jinfeng Rilee
ZMZhikun Ma
Zhikun Ma
JLJiong Li
Jiong Li

27 April 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
GRGrace Jinfeng Rilee
Grace Jinfeng Rilee
SRSenthil Radhakrishnan
Senthil Radhakrishnan
GYGuang-Yu Yang
Guang-Yu Yang
JLJiong Li
Jiong Li
Inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn’s disease, are chronic inflammatory disorders of the gastrointestinal tract associated with epithelial barrier dysfunction, dysregulated immune responses, and an increased risk of cancer. Persistent inflammation is a key driver of IBD-associated tumorigenesis, yet the transcriptional regulators linking inflammatory signaling to epithelial transformation remain incompletely defined. FOSL1 (FOS-like antigen 1), a member of the activator protein-1 (AP-1) transcription factor family, has emerged as a critical mediator at the intersection of inflammation, epithelial homeostasis, and cancer progression. FOSL1 is induced by pro-inflammatory pathways commonly activated in IBD, including MAPK/ERK, NF-κB, and cytokine signaling, and regulates gene programs involved in cell proliferation, migration, barrier integrity, immune modulation, and survival. Accumulating evidence demonstrates that FOSL1 expression is elevated in inflamed intestinal mucosa and in IBD-associated malignancies, where it contributes to epithelial dysfunction, chronic inflammation, tumor initiation, metastasis, angiogenesis, and therapeutic resistance. Moreover, FOSL1-driven transcriptional networks show mechanistic overlap between IBD-associated colorectal cancer (CRC) and other inflammation-linked gastrointestinal cancers, such as pancreatic ductal adenocarcinoma (PDAC). In this review, we summarize current knowledge on the regulation and function of FOSL1 in intestinal inflammation and IBD-associated cancers, highlight its context-dependent roles in epithelial and immune compartments, and discuss emerging therapeutic strategies aimed at indirectly targeting FOSL1 signaling pathways.